The Customer Excellence Glossary for Pharma

Every discipline arrives with a vocabulary, and the vocabulary usually arrives before the discipline has settled. This glossary collects the terms I use to describe how pharmaceutical commercial systems create value and where they lose it. These are not industry-standard definitions. They are the working vocabulary of one practice, set out in The Customer Excellence Enterprise and sharpened since in client work.

Several of the terms below deliberately disagree with how the same words are used elsewhere. Realization Rate means something quite specific to an accountant. Value leakage means something quite specific to a procurement lead. I have kept both words anyway. The pharmaceutical meaning is the one that describes what actually happens between a prescribing decision and a patient on sustained therapy, and a borrowed word with a declared quarrel is more useful than a new word nobody recognises.

A glossary that presents itself as neutral reference is usually making an argument while pretending not to. I would rather declare the argument. What follows is a vocabulary with an author, a point of view and a set of positions that can be checked and contested.

The architecture

Consumer-Grade Pharma

Consumer-Grade Pharma is the standard a pharmaceutical commercial system is held to when patients and prescribers judge it against the best interaction they had anywhere, rather than against another pharmaceutical company. It is the category and the movement that sit at the top of this architecture. The Consumer-Grade Specification behind it is a closed set of six conditions: Recognition, Anticipation, Coherence, Effort, Resolution and Visibility. Thresholds are set per organization rather than handed down.

Consumer-Grade is hyphenated and capitalised because it names a specification and not a mood. Felt attributes such as easy, simple, fast and transparent are reported outcomes that decompose into those six conditions, which is what makes them designable. Pharmaceutical companies are patient-centric by nature, so the change they face is entering the consumer arena where people have choice. The longer account of Consumer-Grade Pharma as a commercial standard works through the conditions one at a time.

Customer Excellence

Customer Excellence is the enterprise capability that designs, delivers and scales coherent experiences across the three paths a customer travels, and that governs whether clinical intent becomes realized therapy. It is the fourth domain of commercial excellence, alongside launch excellence, marketing excellence and sales excellence. It is a pharma-specific interpretation of customer experience rather than an import from another industry. Imported customer experience was rejected in pharma because the first iterations did not fit, so the rejection was rational and the wrong lesson was drawn from it.

Customer Excellence is most often confused with a programme, a department or a training initiative, and it can survive as none of those. It becomes durable only as an enterprise capability living in leadership, organizational, operational and commercial DNA. The case for Customer Excellence as pharma's fourth pillar sets out what that requires of an operating model.

The therapeutic value chain

The therapeutic value chain starts with the science and ends with patient therapy, and the clinical decision is its pivot point. That decision depends on the commercial model, which makes the commercial system part of the chain rather than a layer bolted on after it. The job of the commercial system is to put the state of the art in front of the decision before it is made, then see the decision through.

The consequence is the load bearing part. A molecule that works and does not reach a patient has the same clinical outcome as a molecule that does not work, so a commercial failure is a therapeutic failure. That is the argument I reach for before the arithmetic, and the commercial system's place in the therapeutic value chain develops it properly.

Commercial excellence

Commercial excellence is the discipline of making a pharmaceutical commercial system perform as well as the science it carries. It has been built as three named domains, launch excellence, marketing excellence and sales excellence. Each of the three optimizes the creation of clinical intent. None of them owns whether that intent survives.

Outside pharma the phrase often shrinks to sales effectiveness and pricing discipline, which is a narrower thing than what is meant here. Used properly it names the whole apparatus that carries a medicine from approval to a patient who stays on it, and read that way the gap becomes structural rather than optional. The account of the four domains of pharma commercial excellence explains why the fourth is the one nobody built.

Experience as the third leg

Experience is the third leg of a pharmaceutical value proposition, alongside product and brand, and it is the lived experience of obtaining a medicine and staying on it. Pharma industrialized product and brand with real rigour. Experience was left to default while the other two were designed, which is the enemy in all of this. The three legs do not add together, they multiply.

In the Enterprise Value Realization model, realized value is brand multiplied by product multiplied by experience, raised to the power of culture, and discounted by one minus Customer Value at Risk. Brand, product and experience describe design capability. Customer Value at Risk describes operating performance in a period, and those two roles stay distinct. The treatment of experience as the third leg of the pharma value proposition works through why multiplication rather than addition is the right form.

The measures

Realization Rate in pharma

The Realization Rate of a pharmaceutical brand is realized value divided by earned value, meaning the share of the value earned at a prescribing decision that becomes sustained therapy. Earned value is created when a clinician decides to prescribe. Realized value is what survives the journey to a patient still on therapy. Progression is measured on a stage ladder of Scripts Written, Filled, Therapy Started, 90-Day and Persistence.

Accountants and lawyers use realization rate to mean billed hours against billable hours, and a reader who arrives from that sense has landed in a different field. There the ratio describes how much of recorded time turns into invoiced revenue. Here the numerator is therapy and the denominator is clinical intent, and the thing being measured is whether science reached a human being. The page on the Realization Rate of a pharmaceutical brand keeps that distinction in front of the reader throughout.

Value leakage in pharma

Value leakage in pharma is the therapeutic and commercial value earned when a clinician decides to prescribe and then lost before the patient starts, continues and benefits from therapy. It is the distance between earned value and realized value. No competitor takes the difference. The system between a decision and a dose takes it, quietly, without anyone deciding that it should.

In general business, value leakage usually means contract slippage, the margin that drains out of a signed agreement through unbilled work, unclaimed entitlements and unenforced terms. Pharma has its own adjacent term, revenue leakage, which describes money lost in pricing, rebates and gross to net. Neither of those is what is meant here, and the difference matters because both of them can be fixed in a contract while this one can only be fixed in a journey. The full account of value leakage between a prescribing decision and sustained therapy traces where it occurs.

Customer Value at Risk

Customer Value at Risk is earned value multiplied by one minus the Realization Rate, which expresses value leakage as a forecastable figure. It is the commercial exposure created by friction, fragmentation and failed handoffs inside a commercial system. It requires no translation in a finance conversation. A loss stated in that form can hold a budget line, which a loss stated as a journey map rarely can.

A reader meeting this measure for the first time often assumes it is a shortfall multiplied by net revenue per patient. It is not, and that version produces a smaller and less useful figure, because it describes one period rather than the exposure the system is carrying. Customer Value at Risk shares its page with the arithmetic of pharmaceutical value leakage, because the two are the same observation expressed in different registers.

The three paths

Path to Prescribe

The Path to Prescribe is the first of three journeys where pharmaceutical value is won or lost, running from an undiagnosed patient to a clinical decision. Ownership sits with medical affairs, the field force and marketing, with the brand team named as owner across all three paths. It is the one path pharma has genuinely industrialized, and it deserves respect as such.

The instruments a brand team actually holds sit almost entirely here: prescribing data, market research, message testing, share tracking and promotional response. That is why end to end brand ownership can be real on an organization chart and thin in practice, since the measurement stops where the decision is made. The page on the Path to Prescribe examines what that instrument set can and cannot see.

Path to Fulfill

The Path to Fulfill is the second of three journeys where pharmaceutical value is won or lost, running from a clinical decision to the medicine in a patient's hand. It passes through benefit verification, prior authorization, affordability, specialty pharmacy coordination, onboarding and first fill. Each step is administered by a different party with different incentives and a different definition of done. Almost none of the friction a patient meets here is legally required.

Dropout on this path is commonly read as a payer problem, which is comfortable and largely wrong. The friction is experiential rather than clinical or promotional, and that matters because what was designed can be redesigned. The page on the Path to Fulfill walks the handoffs in the order a patient meets them.

Path to Adhere

The Path to Adhere is the third of three journeys where pharmaceutical value is won or lost, running from a first fill to the duration the clinical trial actually demonstrated. An efficacy claim is a claim about a duration. A patient who stops early did not receive the product that was tested. Some attrition reflects sound clinical judgment or informed patient choice, and that deserves respect rather than intervention.

The distinction worth holding is between attrition that someone chose and attrition that the system absorbed. The second kind is unresolved responsibility wearing the costume of a clinical outcome. The page on the Path to Adhere separates the two and explains how to tell them apart in practice.

The disciplines

Customer consciousness

Customer consciousness is the degree to which customer reality is present in decisions before those decisions are made, rather than sentiment about customers collected after the fact. Raising it is the purpose of Customer Excellence, and the pillars of the practice are the instruments that raise it. In the context of category formation the term also carries an upstream sense. There it means reading a customer's world deeply enough that what their life is making them need becomes visible before any market has formed around it.

Customer consciousness is routinely confused with customer satisfaction, which measures how people felt once the decisions had already been taken. The working test is simpler than any score. Did the decision taken on an ordinary Tuesday have the customer's reality in the room with it. The essay on customer consciousness and the GLP-1 phenomenon shows the upstream sense at work in a category that formed around a need nobody had named.

Predisposition

Predisposition is the condition of an enterprise that is predisposed to deliver exceptional experiences structurally and systematically, rather than through frontline heroics. It describes how a company is built, not any lean a customer holds toward the brand. Heroics work as a subsidy, and a subsidy conceals the design gap it is paying for. Predisposition becomes durable only when Customer Excellence is embedded in leadership, organizational, operational and commercial DNA.

The word is borrowed from marketing, where it usually describes a customer's tilt toward a brand before any purchase, and reversing the direction is the whole point. The question stops being whether customers are predisposed toward the company and becomes whether the company is predisposed toward them. The page on structural predisposition in pharma sets out the four dimensions of DNA it depends on.

Customer intelligence

Customer intelligence is the method by which a commercial system raises its customer consciousness, organized as Context, Orchestration and Progression. Context comes from three listening instruments that compound only in this order: synthetic personas generate the hypothesis, direct voice of the customer tests whether people recognise it, and the frontline confirms whether it is happening. Orchestration is where context becomes continuous progress across channels. Progression is where the work is proved, on the stage ladder.

Taken alone, each instrument produces a defensible artifact and no decision, which is how customer intelligence gets confused with market research. AI accelerates whatever operating system already exists, so an organization that speeds up a quarterly cadence without repairing what it listens to will simply be wrong faster. The hub page on customer intelligence in pharma carries the method and its health measure together.

The instruments

Voice of the frontline

Voice of the frontline is the structured capture of what a company's field force, hub agents, medical information team and patient support staff directly observe. It is the most unimpeachable signal in the commercial system for four reasons that stack. It is observed rather than recalled, account specific rather than sampled, current rather than lagged, and already attached to the moment progression broke.

Voice of the frontline is often mistaken for sales feedback, which travels as anecdote and dies in a meeting. The frontline is one of pharma's most underutilized intelligence systems, encountering barriers long before dashboards detect them. Treating that encounter as intelligence rather than as commentary is the move. The page on voice of the frontline in pharma describes how to capture it without turning it into another report.

Synthetic personas

A synthetic persona is a model generated stand in for a customer, built from existing research and public data, used to produce simulated answers to questions that would otherwise be put to a real person. In pharmaceutical use it is a hypothesis generator rather than a source of truth. Its value collapses when it is validated against itself rather than against observed reality. Simulation fidelity differs sharply by audience, being checkable for physicians, unverifiable for patients and lowest of all for payers.

I own a method here and no platform, and the distinction is worth stating plainly rather than leaving to inference. The instrument comes first in the order of context and last in the order of authority, which is an uncomfortable position for anyone selling it as an answer. The page on synthetic personas in pharma research sets out where the method holds and where it fails.

FieldOS

FieldOS is an operating blueprint for field intelligence and activation in pharma, built around a closed loop of six stages. The stages are Capture Signal, Classify Barrier, Assign Owner, Intervene, Measure Progression, and Learn and Improve. AI sits at the centre of the loop supporting every stage, never as a stage of its own. Components are tailored per organization, because a blueprint describes a direction rather than a product.

FieldOS is about better listening rather than better pre-call planning, which separates it from field AI built to improve what a representative says in the room. Your field force has a lot to say, and the open question in most commercial organizations is whether anyone is listening. The page on the FieldOS operating blueprint describes the loop and what each stage asks of an operating model.

The Transfer Coefficient

The Transfer Coefficient is the proportion of meaningful frontline intelligence that survives the journey from customer observation to consequential organizational action and measured effect. It is the health measure of a customer intelligence capability. A low Transfer Coefficient indicates a research function rather than an intelligence capability. The loss it measures is structural, rarely a failure of attention by anyone in the chain.

Most commercial organizations have never measured it, which is itself the finding worth sitting with. The coefficient shares its page with the Context, Orchestration and Progression method, because it is the only honest way to know whether that method is working or merely running.

Why naming a loss is what makes it fundable

Organizations govern what they can name. A loss without a name has no owner, no budget line and no place on a scorecard, so it gets absorbed rather than managed. Absorption is quiet by nature. It shows up much later as a flat quarter with no obvious cause and a set of explanations that all sound plausible.

The point here is mechanical rather than linguistic. A named loss can be assigned to someone, measured against a baseline and funded with a number, which is how a commercial organization starts governing something it was previously carrying in silence. Vocabulary is the first instrument of governance, and it tends to arrive before the governance does.

Several of these definitions will be argued with, which is the right response to a vocabulary that claims to describe how value behaves. Precise disagreement is more useful to me than vague agreement, and it is how a practice vocabulary earns the right to become a shared one. The definitions above are offered in that spirit.

About the Author

Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.

The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.